Caribou cuts NK cell therapy program, lays off 12% of staff to fund CAR-T priorities.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Abstract:
      Eyeing ways to keep cash flowing into 2026, Caribou has decided preclinical CAR-NK research needs to go—along with 12% of its workforce. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of FierceBiotech is the property of Questex Media Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)